China
Updated
Reviewed by Vidhi Upadhyay
China Climate-Sensitive Disease Diagnostics Market Industry Trends and Forecast to 2034: Segmented by (Disease, Test, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
China · 2024–2034 · placeholder estimates
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.
China (this report) at $287.5 Mn.
India at 10.3% a year.Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.
$311.6 Mn total, 2026–2034
| Year | Market size | Change that year | Since 2025 |
|---|---|---|---|
| 2024 (estimate) | $265.0 Mn | — | — |
| 2025 (base) | $287.5 Mn | +$22.5 Mn | — |
| 2026 (forecast) | $311.9 Mn | +$24.4 Mn | +8.5% |
| 2027 (forecast) | $338.4 Mn | +$26.5 Mn | +17.7% |
| 2028 (forecast) | $367.2 Mn | +$28.8 Mn | +27.7% |
| 2029 (forecast) | $398.4 Mn | +$31.2 Mn | +38.6% |
| 2030 (forecast) | $432.3 Mn | +$33.9 Mn | +50.4% |
| 2031 (forecast) | $469.0 Mn | +$36.7 Mn | +63.1% |
| 2032 (forecast) | $508.9 Mn | +$39.9 Mn | +77% |
| 2033 (forecast) | $552.1 Mn | +$43.3 Mn | +92.1% |
| 2034 (forecast) | $599.1 Mn | +$46.9 Mn | +108.4% |
Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.
US
$1.40 Bn
China (this report)
$287.5 Mn
Canada
$274.3 Mn
Japan
$213.8 Mn
Germany
$127.2 Mn
Brazil
$89.2 Mn
UK
$79.5 Mn
France
$79.1 Mn
Spain
$73.2 Mn
Italy
$69.7 Mn
India
$67.4 Mn
Ecuador
$62.7 Mn
Mexico
$56.5 Mn
Saudi Arabia
$53.2 Mn
Australia
$45.2 Mn
New Zealand
$32.9 Mn
Russia
$32.7 Mn
South Africa
$25.6 Mn
UAE
$18.1 Mn
Egypt
$8.5 Mn
Philippines
$7.8 Mn
Malaysia
$5.7 Mn
Hong Kong
$5.1 Mn
Thailand
$4.6 Mn
Singapore
$4.1 Mn
Kenya
$2.4 Mn
| Market size, 2025 | $287.5 Mn placeholder estimate |
|---|---|
| Forecast, 2034 | $599.1 Mn placeholder estimate |
| Growth (CAGR), 2025–2034 | 8.5% placeholder estimate |
| Years | 2024 historical · 2025 base year · 2026–2034 forecast |
| Segments | Disease and test (see all) |
| Key players | Abbott Laboratories, SD Biosensor, bioMérieux SA, Qiagen N.V., Molbio Diagnostics (see all) |
| Regulator in China | NMPASource: National Medical Products Administration. Checked 14 Nov 2026. |
| Formats | PDF, PPTX, XLSX |
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
Climate-sensitive disease diagnostics detect illnesses spreading with climate change, such as dengue, malaria, cholera and heat illness.
Key segments of the climate-Sensitive Disease Diagnostics market include disease (Dengue, Malaria and Cholera) and test (Rapid Tests and Molecular Tests).
More heatwaves, air pollution, floods and the spread of climate-sensitive diseases are driving the climate-Sensitive Disease Diagnostics market. Health systems are under pressure to cut their own emissions.
Early warning systems, greener hospitals and climate-resilient supply chains give the climate-Sensitive Disease Diagnostics market strong room to grow.
Limited dedicated funding, unclear responsibility between agencies and lack of local data hold back the climate-Sensitive Disease Diagnostics market.
The climate-Sensitive Disease Diagnostics market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
Medical devices are regulated by the National Medical Products Administration (NMPA) and its provincial offices: class I devices are filed, and class II and III devices are registered.[1] Basic medical insurance covers most people; the National Healthcare Security Administration (NHSA) runs it and sets the National Reimbursement Drug List.[2] Deaths from air pollution: 95 per 100,000 people in 2019, the latest WHO figure for China.[3]
[1] National Medical Products Administration. Checked 14 Nov 2026.
[2] National Healthcare Security Administration. Checked 14 Nov 2026.
[3] WHO Global Health Observatory, Deaths from air pollution (per 100,000 people). Retrieved 15 Nov 2026.
Medical device rules, such as the US FDA 510(k) and PMA pathways and the EU Medical Device Regulation, govern how climate-Sensitive Disease Diagnostics products are approved and monitored. Reimbursement codes and hospital purchasing policies decide how widely they are used in China.
What doctors and scientists are doing in Climate-Sensitive Disease Diagnostics right now, from free public sources.
95 per 100,000 people
Deaths from air pollution, China, 2019 (WHO).
Compare every country on the Public Health DashboardSources: PubMed (US National Library of Medicine), ClinicalTrials.gov, WHO Global Health Observatory, World Bank. Fetched 15 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
[1] World Bank Open Data, Deaths from air pollution (per 100,000 people). Retrieved 14 Nov 2026.
[2] World Bank Open Data, Health spending per person (US$ per person). Retrieved 14 Nov 2026.
[3] World Bank Open Data, Doctors (per 1,000 people). Retrieved 14 Nov 2026.
From our blog
China · 2 shared keywords
China · 1 shared keyword
China · 1 shared keyword
China
China
China
Digital Health · China
Healthcare Services · China
Pharmaceuticals · China
OTC & Nutraceuticals · China
Pharmaceuticals · China
Healthcare Services · China